AG
AUPH icon

Ascent Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ascent Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170K Buy
+10,008
New +$160K 0.01% 780

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ascent Group's AUPH Position: Q2 2026 in Review

Ascent Group opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 10,008 shares worth $170K. The stake represents 0.01% of the portfolio and ranks #780 among its holdings.

281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Ascent Group held 10,008 shares of Aurinia Pharmaceuticals worth $170K as of Q2 2026.
  • Aurinia Pharmaceuticals was a new Ascent Group position in Q2 2026.
  • Aurinia Pharmaceuticals made up 0.01% of Ascent Group's portfolio in Q2 2026, its #780 holding.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.